Filtered By:
Condition: Thrombosis
Drug: Clopidogrel
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 536 results found since Jan 2013.
Expert Opinion on P2Y12 Inhibitors Use in Management of Acute Coronary Syndromes: Focus on Ticagrelor
In conclusion, ticagrelor (180 mg, 90 mg, and 60 mg doses), a potent antiplatelet is expected to reshape the antiplatelet use in the management of ACS.PMID:34781659
Source: Journal of the Association of Physicians of India - November 16, 2021 Category: General Medicine Authors: Immaneni Sathyamurthy M S Hiremath Jitendra Pal Sawhney Subhash Chandra Hrudanand Mishra C K Ponde Shuvanan Ray Suhas Hardas Sunil Sathe P C Rath Bagirath R Girish B Navasundi Vilas Magarkar C N Makhale Suvro Banerjee P R Vaidyanathan Amal Kanti Sen Pande Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
